GENSIGHT BIOLOGICS S.A. |
Market Closed -
Other stock markets
|
After market 12:00:35 pm | |||
| 0.418 EUR | +0.97% |
|
0.418 | 0.00% |
| Apr. 05 | GenSight: financial visibility assured until the end of April | CF |
| Mar. 25 | GenSight: share price falls, limited financial visibility | CF |
| Sales 2024 * | 4.4M 4.72M | Sales 2025 * | 7.4M 7.94M | Capitalization | 32.3M 34.65M |
|---|---|---|---|---|---|
| Net income 2024 * | -26M -27.89M | Net income 2025 * | -25M -26.81M | EV / Sales 2024 * | 20.5 x |
| Net Debt 2024 * | 57.8M 62M | Net Debt 2025 * | 85.7M 91.92M | EV / Sales 2025 * | 15.9 x |
| P/E ratio 2024 * |
-0.73
x | P/E ratio 2025 * |
-0.74
x | Employees | 16 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.4% |
More Fundamentals
* Assessed data
More news
Latest transcript on GenSight Biologics S.A.
More press releases
More news
| 1 day | +3.38% | ||
| 1 week | +4.39% | ||
| Current month | +6.47% | ||
| 1 month | +6.73% | ||
| 3 months | +3.01% | ||
| 6 months | -30.29% | ||
| Current year | -6.96% |
1 week
0.40
0.43
1 month
0.380.43
Current year
0.300.60
1 year
0.301.15
3 years
0.3010.08
5 years
0.3010.08
10 years
0.3010.82
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 21-05-18 | |
Scott Jeffers
CTO | Chief Tech/Sci/R&D Officer | - | 22-03-31 |
Magali Taiel
CTO | Chief Tech/Sci/R&D Officer | - | 18-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Wyzga
CHM | Chairman | 69 | 13-09-30 |
Cédric Moreau
BRD | Director/Board Member | 37 | 19-06-10 |
Maritza McIntyre
BRD | Director/Board Member | 58 | 19-06-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 0.418 | +0.97% | 23 048 |
| 24-04-24 | 0.414 | +1.72% | 31,346 |
| 24-04-23 | 0.407 | -0.61% | 2,959 |
| 24-04-22 | 0.4095 | -0.12% | 26,841 |
| 24-04-19 | 0.41 | 0.00% | 21,651 |
Real-time Euronext Paris, April 25, 2024 at 04:50 am EDT
More quotes
GenSight Biologics S.A. specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives.
At the end of 2023, the company had a portfolio of 2 products, including 1 in phase III clinical development (Lumevoq for the treatment of Leber's hereditary optic neuropathy) and 1 in phase I/II clinical development (GS030 for the treatment of retinitis pigmentosa).
Calendar
2024-05-28
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
0.414
EUR
Average target price
0.4
EUR
Spread / Average Target
-3.38%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -6.96% | 34.52M | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +1.11% | 22.2B | |
| -16.53% | 21.23B | |
| -8.31% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
- Stock Market
- Equities
- SIGHT Stock
